MDxHealth SA (BSE:MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that its MGMT test (Predict MDx for Brain) has demonstrated success in personalizing brain cancer treatment in a major international phase III study. The data, obtained from a Phase III study (RTOG 0525) of temozolomide will be presented at the Annual Meeting of the American Society for Clinical Oncology (ASCO, Chicago, USA, 3-7 June) by principal investigator Mark R. Gilbert, MD (University of Texas M. D. Anderson Cancer Center) on Sunday 5th June.
